Samsung Bioepis’ Ophthalmology Biosimilar Candidate Receives Clinical Approvals in 8 Markets

SEOUL, June 15 (Korea Bizwire) — South Korean pharmaceutical firm Samsung Bioepis Co. said Monday that it has won approvals in major countries to conduct clinical trials for its new ophthalmology biosimilar candidate. SB15 is a biosimilar candidate referencing Regeneron Pharmaceuticals Inc.’s Eylea, a blockbuster therapy to treat age-related (wet) macular degeneration (AMD). It is [...]